Latest ISN Journal Editorial Selections
Results From Part A of the Multi-center, Double-blind, Randomized, Placebo-controlled Nefigard Trial, Which Evaluated Targeted-release Formulation of Budesonide for the Treatment of Primary Immunoglobulin A Nephropathy
To verify the findings of the 2b NEFIGAN trial, the phase 3 NefigArd trial tested the efficacy and safety of nine months of treatment with Nefecon® versus placebo in adult patients with primary IgAN at risk of progressing to kidney failure.
Nefecon® was well-tolerated and most adverse effects were mild to moderate in severity and reversible, confirming outcomes from the phase 2b NEFIGAN study.
Kidney International Reports:
This study evaluated the feasibility of conducting a randomized clinical pilot study to measure the effects of intradialytic yoga on quality of life, self-efficacy, and physical performance among maintenance hemodialysis patients. The feasibility and safety of such a trial were supported by the results.